Our Take
A supply chain problem with no announced fix is now officially a multi-year crisis, and hospitals have had months to adjust procurement but likely haven't.
Why it matters
Breast biopsies are routine diagnostic procedures; sustained needle shortages delay diagnosis and force clinicians to choose between rationing and sourcing unreliable alternatives. This affects every hospital system with an imaging department.
Do this week
Procurement: audit your needle inventory and alternative supplier relationships before Q1 2025 so you can lock secondary sourcing now rather than compete for scraps mid-shortage.
Hologic's withdrawal triggered a multi-year supply gap
The FDA issued a warning that shortages of certain breast biopsy needles will persist into 2027 (per MedTech Dive reporting). The shortage began when Hologic, a major supplier, removed specific biopsy needle products from the market in January. No timeline for resolution or alternative product availability has been announced publicly.
Breast biopsy needles are critical diagnostic tools used to obtain tissue samples for pathology evaluation. When supplies tighten, hospitals face immediate operational pressure: cancel or delay procedures, ration devices across patients, or source from secondary suppliers of uncertain quality and regulatory standing.
This is a diagnosis and trust problem, not just logistics
Breast imaging departments operate on tight schedules. When needle supplies constrain, the delay cascades. A patient waiting for biopsy results experiences anxiety and clinical uncertainty. A hospital managing backlogs may offer older imaging modalities or refer to competitors. Neither outcome is invisible to patients or payers.
The FDA warning, issued months after Hologic's withdrawal, suggests the agency is now formally acknowledging what hospitals have already learned: this is not a short-term disruption. A 2027 persistence horizon means hospitals cannot hope this resolves within a fiscal cycle. They must assume structural unavailability and plan accordingly, or risk diagnostic delays becoming systemic.
The absence of a named replacement product or supplier commitment deepens the uncertainty. Hospitals cannot simply switch vendors; they must qualify new equipment, retrain staff, and negotiate pricing in a constrained market where competitors face identical shortages.
Procurement and supply chain action
Do not wait for the FDA or Hologic to announce a fix. Audit your current needle inventory now: how many procedures are you covering at current consumption rates, and when will you run out? Identify secondary suppliers (including international sources if regulatory pathways permit) and begin qualification conversations immediately. Build relationships with other hospitals and imaging networks to share intelligence on sourcing success and failure.
If your institution has not yet experienced shortages, you are in the lead position to lock favorable terms with secondary suppliers before demand crushes their capacity. Act before your competitors do.